Cannabis for Epilepsy

Epilepsy is one of the most common neurological disorders in the world, affecting over 50 million people globally and approximately 3.4 million in the United States alone. Characterized by recurrent, unprovoked seizures, epilepsy can be profoundly disabling when conventional treatments fail. Up to one-third of patients with epilepsy are classified as having drug-resistant or refractory epilepsy — meaning that two or more antiepileptic drugs (AEDs) have not adequately controlled their seizures.

It is precisely for these patients that cannabis-based medicine has attracted such intense scientific and medical interest. The history of cannabis use for seizures actually stretches back thousands of years — ancient Indian and Chinese medical texts reference cannabis preparations for convulsive disorders. However, rigorous scientific investigation began in earnest only in the latter half of the 20th century, gaining significant momentum when families of children with catastrophic epilepsy syndromes began publicly reporting dramatic improvements after using high-CBD cannabis oil.

Today, cannabis for epilepsy occupies a unique position: it is the area of cannabis medicine with the strongest clinical evidence base, having produced the first ever FDA-approved cannabis-derived pharmaceutical drug. This page explores the science, the evidence, the practical considerations, and the legal landscape surrounding cannabis as a therapeutic option for people living with epilepsy.

What Is Epilepsy?

Epilepsy is a chronic neurological condition defined by a predisposition to generate spontaneous, recurrent seizures. Seizures arise from abnormal, excessive, or synchronous neuronal activity in the brain. They can range from brief lapses of attention (absence seizures) to prolonged, full-body convulsions (tonic-clonic seizures). Epilepsy encompasses dozens of distinct syndromes, each with unique causes, seizure types, and treatment responses. Some epilepsy syndromes — including Dravet syndrome, Lennox-Gastaut syndrome (LGS), and CDKL5 deficiency disorder — are particularly severe, begin in infancy or early childhood, and are highly resistant to conventional therapies.

The endocannabinoid system and Seizure Activity

To understand why cannabis may help with epilepsy, it's essential to understand the endocannabinoid system (ECS). The ECS is a complex cell-signaling network present throughout the central nervous system, comprising endogenous cannabinoids (endocannabinoids), cannabinoid receptors (primarily CB1 and CB2), and the enzymes that synthesize and degrade them. CB1 receptors are highly concentrated in brain regions involved in seizure generation, including the hippocampus, cortex, and basal ganglia. The ECS plays a critical modulatory role in balancing excitatory and inhibitory neurotransmission — the very balance that is disrupted in epilepsy. Research suggests that endocannabinoid signaling acts as a natural "seizure brake," and that enhancing or modulating this system with phytocannabinoids like CBD may reduce seizure frequency and severity.

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid found abundantly in the cannabis plant. Unlike THC, CBD does not produce intoxicating effects and acts through multiple distinct mechanisms that are particularly relevant to epilepsy. The scientific interest in CBD for seizure disorders gained explosive momentum following widely publicized cases — most notably that of Charlotte Figi, a young girl with Dravet syndrome whose severe seizures were dramatically reduced by a high-CBD, low-THC cannabis extract developed by a Colorado family and later named Charlotte's Web.

These anecdotal reports spurred formal clinical investigation, ultimately producing rigorous randomized controlled trials and, in 2018, the FDA approval of Epidiolex (cannabidiol oral solution), the first plant-derived cannabis medicine approved for any condition. Understanding how CBD exerts its antiepileptic effects requires examining its diverse pharmacological targets.

Mechanisms of Action

CBD's antiseizure mechanisms are numerous and not fully elucidated, which is one reason it may work in cases where conventional AEDs with more targeted mechanisms fail. Identified mechanisms include:

• GPR55 receptor antagonism: GPR55 is a receptor that, when activated, promotes neuronal excitability. CBD acts as an antagonist at GPR55, potentially reducing excessive neuronal firing.
• TRPV1 channel modulation: CBD activates transient receptor potential vanilloid type 1 (TRPV1) channels, which may help regulate calcium signaling and neuronal excitability.
• Sodium channel inhibition: CBD has been shown to inhibit voltage-gated sodium channels, a mechanism shared by several established AEDs such as phenytoin and carbamazepine.
• Enhancement of adenosine signaling: CBD may inhibit adenosine reuptake, increasing extracellular adenosine, which has endogenous antiseizure properties through A1 receptor activation.
• Modulation of intracellular calcium stores: CBD affects calcium dynamics at the mitochondrial level and via G-protein-coupled receptors.
• Anti-inflammatory effects: Neuroinflammation is increasingly recognized as a driver of seizure activity, and CBD's potent anti-inflammatory properties may contribute to seizure reduction indirectly.

Key Clinical Trials and Research Data

The clinical evidence for CBD in epilepsy is more robust than for virtually any other cannabis-related medical application. Multiple Phase 3 randomized controlled trials have been published in peer-reviewed journals including The New England Journal of Medicine and The Lancet Neurology. These trials consistently demonstrated that pharmaceutical-grade CBD (Epidiolex) significantly reduced seizure frequency compared to placebo in patients with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex — all highly treatment-resistant conditions.